Tiamfenikol

Quick links to important sections

Tiamfenikol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tiamfenikol

Tiamfenikol is an antibiotic and an antimicrobial agent used to control specific bacterial infections by limiting their ability to grow and multiply.

Property Description
Active ingredient Thiamphenicol (INN)
Form Powder (for reconstitution), Injectable preparations
Pharmacological class Antibiotic; Amphenicol class
Common use Combating bacterial infections
Origin Synthetic, Semisynthetic derivative

Tiamfenikol: Definition, Type, and Origin

The medicinal substance is chemically defined as Thiamphenicol (INN), an antibiotic belonging to the amphenicol class. The medicine is classified under the ATC code J01BA02. This classification indicates the drug's fundamental function: combating susceptible bacterial pathogens.

Thiamphenicol is a synthetic small molecule that acts as a semisynthetic derivative of the older antibiotic Chloramphenicol. This structural difference is the absence of a nitro group, replaced by a methylsulfonyl group, a substitution that influences its metabolic profile compared to its predecessor.


Composition, Forms, and General Purpose

The medicinal product is based on the single active ingredient, Thiamphenicol (C12H15Cl2NO5S). As an INN, Tiamfenikol is available across various international markets under different trade names, such as Urfamycin or Thiocymetin. These preparations are typically supplied in dosage forms such as a sterile powder requiring reconstitution into a liquid solution or as ready-to-use injectable preparations.

These formulations support multiple routes of administration, including oral, intramuscular (IM), and intravenous (IV) delivery. The overall therapeutic purpose of Tiamfenikol is the management of infections, such as those that might arise in the respiratory or urinary tract. Its action is bacteriostatic, a function that limits the growth and reproduction of bacteria, thereby giving the body’s natural immune response the necessary advantage to clear the residual infection.

What side effects are possible with Tiamfenikol?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety profile of Tiamfenikol, as published in authoritative government regulatory documents.

Serious and Clinically Significant Adverse Reactions

The most significant safety concern associated with Tiamfenikol is hematological toxicity, which includes bone marrow depression. This can manifest as a dose-related, reversible decrease in blood cells, such as reticulocytopenia, leukopenia, and thrombocytopenia, and necessitates regular monitoring of blood counts for individuals on prolonged therapy. The drug is structurally related to Chloramphenicol, which has been linked to rare but serious and often irreversible aplastic anemia, a risk that is also considered in the safety profile of Tiamfenikol.

Other Documented Adverse Reactions

Adverse reactions documented across various System-Organ Classes (SOCs) include:

  • Blood and Lymphatic System Disorders: Leukopenia, thrombocytopenia, and other myelosuppression effects.
  • Gastrointestinal Disorders: Nausea, vomiting, and diarrhea.
  • Nervous System Disorders: Peripheral neuropathy, headache, and psychiatric disorders.
  • Hepatobiliary Disorders: Liver enzyme abnormalities.

Population-Specific Safety Considerations

The official safety information highlights specific considerations for vulnerable groups:

  • Pregnancy and Breastfeeding: The use of Tiamfenikol during pregnancy requires a careful assessment of benefits versus potential fetal risks. The drug is known to be excreted in breast milk, posing a risk of adverse effects in the nursing infant, and its use is generally restricted.
  • Neonates/Premature Infants: Neonates and premature infants are at an increased risk of toxicity due to the reduced capacity to metabolize the drug, potentially leading to accumulation.

Safety Monitoring and Limitations

Due to the risk of hematological toxicity, the regulatory profile mandates periodic monitoring of hematological parameters (e.g., full blood cell count) for patients receiving Tiamfenikol over an extended period. Caution and monitoring are also specified for use in patients with pre-existing bone marrow suppression or those receiving other drugs known to cause myelosuppression.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Profile

Tiamfenikol (Thiamphenicol) is an antibiotic closely related to chloramphenicol, and its safety profile requires careful consideration, particularly in overdose situations. Specific, high-level official guidance strictly defining human overdose manifestations and emergency procedures from major regulatory agencies is limited or not widely published.

However, due to the drug’s known ability to affect hematopoiesis—the process of blood cell formation—the primary concern in cases of overexposure or prolonged high dosage is dose-dependent, reversible bone marrow suppression. This is a potential risk because the drug may inhibit protein synthesis in human mitochondrial cells. Although Tiamfenikol is considered to have a lower risk of the rare, irreversible aplastic anemia compared to chloramphenicol, the risk of general bone marrow suppression remains. Clinical manifestations of this toxicity may include reduced levels of red blood cells, white blood cells, and platelets, potentially leading to anemia and increased vulnerability to infection.

When to Seek Medical Attention

Any suspected over-ingestion of Tiamfenikol, whether accidental or intentional, requires immediate emergency medical attention. Contact a Poison Control Center or emergency services immediately if:

  • An unusually large dose has been taken.
  • Symptoms of severe illness, such as persistent vomiting, profound weakness, unusual bleeding or bruising, or signs of serious infection, are experienced.

General supportive care is typically the primary management for drug overexposure, and any treatment should be determined by a healthcare professional in a clinical setting.

Therapeutic Uses of Tiamfenikol

What Tiamfenikol Treats: Main Uses and Benefits

Tiamfenikol is generally relevant for managing symptoms associated with conditions involving inflammatory or irritative processes, and for easing the resulting discomfort. This medication is commonly used across domains where additional symptomatic support is needed during periods when patients experience these types of symptoms.

It is generally applied in conditions presenting with acute episodes and is relevant for managing symptomatic manifestations in the respiratory tract, urinary tract, and certain soft tissue areas.

Quick Fact: Relief for Systemic and Localized Discomfort

This treatment is applied in addressing symptoms related to systemic imbalance, such as fever and general sickness, as well as symptoms related to inflammatory or irritative states, like pain and swelling. “It helps address symptom clusters that may become intense or disruptive and contributes to improved day-to-day comfort.”

It supports patients during difficult episodes by easing the discomfort and assists with managing uncomfortable symptoms that interfere with daily functioning, such as painful urination or a productive cough.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Official regulatory documents define specific populations who must not use Tiamfenikol (Thiamphenicol) due to the risk of serious adverse effects or lack of established safety.

Contraindicated Populations Restricted Populations (Use with Caution)
Individuals with known hypersensitivity to Tiamfenikol or Chloramphenicol. Patients with existing severe renal or liver impairment.
Patients with bone marrow disorders or a history of blood dyscrasias. Premature and newborn babies (under 4 weeks).
Pregnant and breastfeeding women. Patients with acute heart failure or myocardial ischemia.

Tiamfenikol is formally contraindicated for individuals with a known allergy to the drug or related compounds. It is also prohibited for patients with pre-existing disorders of the blood-forming organs, such as bone marrow depression, due to the risk of exacerbating hematologic toxicity.

Regulatory warnings advise against use in pregnancy and lactation as the drug may cross the placenta and is excreted in breast milk, presenting a risk to the infant. Furthermore, its use is restricted in patients with severe renal impairment because the drug's half-life is significantly prolonged in the presence of reduced kidney function, requiring cautious administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented interactions for Tiamfenikol (Thiamphenicol) based on authoritative regulatory and scientific sources, focusing on potential combinations that may alter drug exposure or result in additive toxicity.

Contraindicated and Major Interactions

Interaction Type Interacting Agent Category Practical Implication
Additive Toxicity Other myelosuppressive agents (e.g., chemotherapy, immunosuppressants) Co-administration is generally restricted due to the increased risk of severe, irreversible bone marrow suppression.

Significant Pharmacodynamic and Pharmacokinetic Interactions

Mechanism Interacting Agent Category Observed Effect
Pharmacodynamic Oral Anticoagulants (e.g., Coumarin derivatives) May increase the risk or severity of bleeding.
Pharmacokinetic Certain CYP450 Substrates (e.g., Phenytoin) Tiamfenikol may inhibit the metabolism of certain co-administered drugs, potentially increasing their plasma concentrations and toxicity risk.

Other Documented Interactions

  • Live Bacterial Vaccines: Tiamfenikol may reduce the therapeutic effect of live vaccines.
  • Agents Affecting Excretion: Substances like Bromhexine have been noted in some regulatory content as potentially increasing the excretion rate of Tiamfenikol.

Population-Specific Notes

Interaction risk and severity are significantly magnified in neonates and infants due to their reduced ability to metabolize and excrete the drug, requiring special caution and potential dose modification when co-administering any interacting medicine.

Mechanism of Action

The Core Mechanism: Inhibiting Bacterial Protein Synthesis

Tiamfenikol acts by targeting the bacterial 70S ribosome, specifically binding to the 50S ribosomal subunit. The drug occupies a site at the peptidyl transferase center (PTC). This interaction functions as an inhibitor, physically blocking the enzyme required for the formation of peptide bonds between amino acids, a fundamental step in the translation pathway.


Pathway Effect: Arresting Cellular Proliferation

By suppressing protein synthesis, Tiamfenikol arrests the bacteria’s ability to generate the structural and enzymatic components necessary for replication and growth. This pathway interference results in a bacteriostatic effect, modulating the growth dynamics of the pathogen population by inhibiting proliferation.


Mechanistic Selectivity and Interaction Potential

While the drug exhibits selectivity for the prokaryotic 70S structure over the host's cytoplasmic 80S ribosome, Tiamfenikol must penetrate the cell membrane to access the target. Furthermore, the molecule retains a potential for interaction with host mitochondrial ribosomes, which structurally resemble the bacterial 70S subunit. This indicates a limitation where interference with host cellular processes, particularly protein synthesis in highly proliferative cells, is possible.

Dosage and Administration Information

The official instructions for using Tiamfenikol are structured around specific administration parameters that must be strictly followed to ensure correct use.

Official Administration Guidelines

Administration Scope Required Instruction
Route of Administration Typically Oral or Injection (Intramuscular/Intravenous).
Frequency Pattern Daily administration, often subdivided (e.g., two daily treatments).
Duration of Treatment A fixed course, such as up to 7 days, must be completed as prescribed.
Preparation Requirement For injectable forms, the powder must be dissolved in an appropriate solvent (e.g., water for injection) prior to administration.

Dosage and Procedural Structure

The required Dosage is calculated based on factors such as body weight. For instance, doses of up to 50 mg/kg of body weight are specified for administration by injection. When the daily dose is to be given via injection, it is officially required to be subdivided into two separate treatments.

Special Population Adjustments are necessary, as dosing must be adjusted in patients with renal impairment. The procedural structure involves calculating the precise dose, preparing the formulation if needed (such as dissolution for injection), and then administering the dose according to the mandatory daily frequency until the full Duration of Treatment is completed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tiamfenikol

Evidence for Use in Acute and/or Exacerbated Respiratory Tract Infections

Comparative clinical trials and Randomized Controlled Trials (RCTs) have explored Tiamfenikol's evaluation in adult patients with acute respiratory conditions, such as tracheobronchitis. Researchers in these settings examined outcomes related to physical discomfort, symptom change, and overall clinical response. Findings describe patterns observed in studies where investigators reported on measured changes. The available evidence often relates to specific derivative forms of the medication. Uncertainty: Long-term effects are not fully established as follow-up durations were limited. Comparative data against contemporary standard treatments are restricted.

Evidence for Use in Systemic Bacterial Infections

Tiamfenikol was evaluated in comparative RCTs and retrospective studies for general systemic bacterial infections across various age groups. Research monitored outcomes related to bacteriological eradication and systemic or functional imbalance. The observed results were reported relative to control agents in these comparative trials. Uncertainty: Much of the research is historical or regional. Evidence is limited for long-term outcomes, and comparisons against modern, broad-spectrum antibiotics are restricted.

Research on Drug-Resistant Organisms (Pre-clinical Focus)

Activity against drug-resistant organisms has been explored only through pre-clinical, laboratory-based in vitro activity studies. These studies monitored the Minimum Inhibitory Concentration (MIC) against bacterial strains known to carry macrolide or quinolone resistance. Uncertainty: This evidence is entirely preliminary; it reflects laboratory conditions, not confirmed clinical outcomes in human patients. Insufficient clinical data exist to validate these findings.

Long-Term Outcomes and Follow-up Data

Across most acute infection studies, follow-up durations were limited, usually covering the time interval necessary to complete treatment. Long-term effects are not fully established based on available study summaries. Data on the durability of the observed clinical response remain limited.

Key Uncertainties and Research Gaps

The overall evidence landscape suggests several key uncertainties. Sample sizes were modest in many focused trials, and evidence quality varies across studies. Subgroup findings are uncertain due to insufficient data to confidently generalize results to all patient types, including those with certain comorbidities. Comparative evidence is lacking against many newer standard-of-care antibiotics used today. These research limitations highlight what is known—and what is still uncertain—about Tiamfenikol.

Frequently Asked Questions (FAQ)

Common questions about Tiamfenikol (FAQ)


Q: Why is Tiamfenikol sometimes used when other antibiotics aren't?

According to official product information, Tiamfenikol is officially indicated for specific bacterial infections where laboratory tests confirm the responsible bacteria are susceptible to the drug. Its use may be limited to specific circumstances or pathogens due to its structural class and toxicity profile compared to other treatments.


Q: Is it normal to feel a bit nauseous when starting Tiamfenikol?

Nausea is a frequently documented adverse reaction associated with Tiamfenikol. Gastrointestinal issues such as nausea, vomiting, and diarrhea are reported in official product information, and they are common side effects with many antibiotics.


Q: Is Tiamfenikol safe for elderly patients?

Official information indicates that dose adjustment is often required for patients with reduced kidney function (renal impairment), which is more common in the elderly population. The need for adjustment is based on how Tiamfenikol is eliminated from the body. Safety in this population is determined by the prescriber based on the patient's full medical profile.


Q: Can children take Tiamfenikol, and is the liquid form common?

Tiamfenikol is specifically contraindicated or used with extreme caution in premature and newborn babies (neonates) due to their limited ability to properly process the drug. Eligibility for older children is based on individual assessment and is generally calculated according to body weight. Tiamfenikol is commonly supplied as a sterile powder that must be mixed with a solvent to create a liquid solution for oral or injectable administration.


Q: What should someone do if they miss a dose of Tiamfenikol?

Official regulatory information typically addresses how to handle a missed dose, which generally involves taking the dose if remembered soon after the scheduled time. However, if it is nearly time for the next dose, the missed dose is usually skipped. It is crucial to maintain the required treatment frequency and not to take a double dose.


Q: Is Tiamfenikol generally considered a safe drug for short courses?

The most significant safety concern in official documents is hematological toxicity (bone marrow depression), which is primarily associated with prolonged therapy. Regulatory documents emphasize the need for blood monitoring during extended use, which suggests that short, defined courses carry a lower risk of such severe effects.


Q: Can a patient stop taking Tiamfenikol if their symptoms disappear early?

Official administration guidelines strictly state that the fixed course must be completed as prescribed. Stopping the antibiotic early can increase the risk of the infection returning or contributing to bacterial resistance, even if the symptoms have improved.


Q: What is the risk of developing resistance to Tiamfenikol?

The risk of bacterial resistance developing is a concern with any antibiotic. Regulatory bodies explicitly state that the full prescribed duration of Tiamfenikol treatment must be completed to minimize the chance of bacteria surviving and developing resistance to the drug.


Q: Does Tiamfenikol interfere with vaccination schedules?

Yes, official warnings exist regarding an interaction with certain vaccines. Tiamfenikol may reduce the therapeutic effect of live bacterial vaccines, and consultation with a healthcare provider is necessary before co-administration.


Q: What is the maximum duration someone can safely take Tiamfenikol?

The treatment duration is determined by the prescribing physician based on the specific infection. The regulatory documentation describes treatment courses as fixed, often lasting 'up to 7 days.' The duration is limited to minimize the risk of cumulative side effects, particularly hematological toxicity.


Q: How long does Tiamfenikol stay in your system after the last pill?

Tiamfenikol is eliminated relatively quickly by the body, mainly through the kidneys. Official pharmacokinetic data indicates that the elimination half-life is typically between two and five hours. The drug is rapidly eliminated, with most of the medication clearing the body within 24 to 48 hours.


Q: Can Tiamfenikol cause sleepiness or affect driving?

Adverse reactions listed under Nervous System Disorders include peripheral neuropathy and headache. Official warnings advise caution regarding the ability to drive or operate machinery if the drug causes dizziness or other central nervous system (CNS) effects.


Q: Is Tiamfenikol a penicillin-based drug?

No, Tiamfenikol is not a penicillin-based drug. It belongs to the amphenicol class of antibiotics and is a derivative of Chloramphenicol. This distinction is important for people with known allergies to penicillin.


Q: Does Tiamfenikol come in different strengths, and what are they?

Tiamfenikol is supplied in various dosage forms, most commonly as a sterile powder that requires mixing, or as injectable preparations. The specific commercial strength (e.g., amount of drug per vial or capsule) is dependent on the manufacturer's formulation.


Q: Are generic versions of Tiamfenikol as effective as the brand-name versions?

In countries where generic versions are approved by regulatory agencies, these products are generally classified as therapeutically equivalent to the brand-name drug. This means they must contain the identical active ingredient in the same dosage form and meet the same official standards for safety and efficacy.


Q: Is there any evidence that Tiamfenikol can cause mood changes?

Official adverse reaction listings include psychiatric disorders under the Nervous System Disorders category. While this is a broad term, it covers the potential for various mental health effects, including mood disturbances, and any changes should be reported to a healthcare provider.


Q: Can Tiamfenikol be crushed or chewed if someone has trouble swallowing pills?

The administration instructions in regulatory documents specify the proper preparation and route of use for the medication. For many oral formulations, instructions for administration do not permit modification like crushing or chewing. In these cases, the drug is often provided in alternate dosage forms, such as a powder for reconstitution (liquid).


Q: Do people typically experience stomach pain from Tiamfenikol?

The drug is officially associated with common Gastrointestinal Disorders, which include documented reactions like nausea, vomiting, and diarrhea. While specific stomach pain may not be listed separately, it is often a related symptom of these documented gastrointestinal issues.

How should Tiamfenikol be stored and disposed of?

How to Store and Dispose of Tiamfenikol

Tiamfenikol (Thiamphenicol) must be stored and handled according to specific regulatory requirements to ensure product integrity and safety.


Storage Requirements

  • Temperature and Light: The medicine must be stored at a temperature below 25°C and must be protected from light. It is essential that the product is not frozen.
  • Container and Stability: The container must be kept tightly closed to protect it from moisture. For some preparations, a specific shelf life, such as 28 days, applies after the first opening of the immediate packaging.
  • Child Safety: Store the medicine in a location that is securely out of the sight and reach of children.

Disposal Instructions

Expired or unused Tiamfenikol must not be disposed of via wastewater or household waste. Official regulatory requirements instruct that disposal must utilize designated local take-back schemes or national collection systems in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tiamfenikol found in:

A-Z Index: